Profile data is unavailable for this security.
About the company
Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceutical’s products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies Paracetamol, Metformin, Guaifenesin, and Methocarbamol APIs. It has over seven manufacturing facilities, approximately six of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. The Company’s wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.
- Revenue in INR (TTM)45.06bn
- Net income in INR4.05bn
- Incorporated1991
- Employees4.12k
- LocationGranules India Ltd2nd Floor3rd Block, My Home Hub MadhapurHYDERABAD 500081IndiaIND
- Phone+91 4 069043500
- Fax+91 4 023115145
- Websitehttps://granulesindia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma Advanced Research Co Ltd | 755.45m | -3.87bn | 73.56bn | 409.00 | -- | 58.49 | -- | 97.37 | -11.93 | -11.93 | 2.33 | 3.88 | 0.1123 | 22.11 | 2.32 | 1,847,073.00 | -57.57 | -61.70 | -85.94 | -119.31 | 62.76 | 74.49 | -512.56 | -163.40 | 1.01 | -244.66 | 0.3272 | -- | -68.36 | -16.21 | -73.96 | -- | 15.40 | -- |
| Blue Jet Healthcare Ltd | 7.12bn | 1.64bn | 77.43bn | -- | 47.27 | 9.16 | 40.36 | 10.88 | 9.44 | 9.44 | 41.04 | 48.73 | 0.7409 | 2.46 | 3.42 | -- | 17.05 | -- | 21.25 | -- | 55.82 | -- | 23.01 | -- | 2.80 | 1,257.13 | 0.00 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| F D C Ltd | 19.43bn | 3.05bn | 81.75bn | 6.37k | 26.98 | 3.90 | 23.70 | 4.21 | 18.61 | 18.61 | 118.69 | 128.81 | 0.8077 | 1.83 | 16.19 | -- | 12.68 | 12.05 | 14.56 | 13.73 | 66.23 | 62.81 | 15.70 | 15.85 | 2.18 | 74.02 | 0.0097 | -- | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 86.88bn | 1.41k | 40.62 | -- | 36.08 | 7.43 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Marksans Pharma Ltd | 21.77bn | 3.14bn | 90.78bn | 1.40k | 28.91 | 4.40 | 23.33 | 4.17 | 6.93 | 6.93 | 48.11 | 45.57 | 0.894 | 1.88 | 5.01 | -- | 12.93 | 14.62 | 15.36 | 18.52 | 52.32 | 51.22 | 14.46 | 14.03 | 3.19 | 34.30 | 0.1048 | 6.66 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Strides Pharma Science Ltd | 40.51bn | -1.25bn | 93.90bn | 2.85k | -- | 4.42 | 130.15 | 2.32 | -13.86 | -7.93 | 445.06 | 231.29 | 0.6493 | 1.44 | 3.32 | -- | -2.38 | -1.68 | -4.43 | -2.97 | 59.50 | 52.74 | -3.67 | -3.36 | 0.64 | 1.07 | 0.5485 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Glenmark Life Sciences Ltd | 22.93bn | 4.47bn | 104.23bn | 1.82k | 23.36 | -- | 20.76 | 4.54 | 36.41 | 36.41 | 186.83 | -- | -- | -- | -- | -- | -- | 18.28 | -- | 30.03 | 54.58 | 53.40 | 19.49 | 20.23 | -- | 389.45 | -- | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Neuland Laboratories Ltd. | 15.59bn | 3.00bn | 107.48bn | 1.65k | 35.82 | 8.38 | 29.87 | 6.90 | 233.89 | 233.89 | 1,214.81 | 999.78 | 0.9135 | 2.33 | 4.24 | 9,457,406.00 | 17.59 | 9.25 | 23.58 | 12.71 | 52.92 | 47.81 | 19.25 | 11.99 | 1.33 | 28.78 | 0.0692 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 114.73bn | 1.03k | 20.77 | -- | 12.32 | 1.68 | 34.89 | 34.89 | 431.45 | -- | -- | -- | -- | -- | -- | 2.96 | -- | 3.55 | 68.13 | 69.37 | 8.01 | 5.13 | -- | 2.34 | -- | 24.69 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 116.10bn | 777.00 | 25.50 | 5.01 | 22.55 | 6.85 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | -- | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | -- |
| Wockhardt Ltd | 27.98bn | -4.63bn | 130.90bn | 2.39k | -- | 3.90 | -- | 4.68 | -32.08 | -32.08 | 194.04 | 218.97 | 0.365 | 1.80 | 3.95 | 11,687,550.00 | -6.16 | -4.56 | -11.11 | -8.29 | 58.36 | 55.26 | -16.87 | -12.70 | 0.5532 | -0.1594 | 0.3915 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Granules India Ltd | 45.06bn | 4.05bn | 136.48bn | 4.12k | 33.67 | 4.23 | 22.28 | 3.03 | 16.72 | 16.72 | 185.99 | 133.08 | 0.8645 | 1.60 | 4.66 | 10,932,480.00 | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 48.83 | 8.99 | 11.82 | 0.7444 | 6.13 | 0.2896 | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Eris Lifesciences Ltd | 20.09bn | 3.92bn | 146.08bn | 3.55k | 37.30 | 5.65 | 25.20 | 7.27 | 28.78 | 28.78 | 147.52 | 190.12 | 0.375 | 2.37 | 5.62 | -- | 7.41 | 13.42 | 11.22 | 16.80 | 81.08 | 80.29 | 19.76 | 24.96 | 0.8345 | 5.80 | 0.4633 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Sanofi India Ltd | 28.47bn | 5.49bn | 153.74bn | 2.17k | 28.00 | -- | 26.10 | 5.40 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Concord Biotech Ltd | 10.17bn | 3.08bn | 178.12bn | 1.38k | 57.84 | 11.67 | 49.25 | 17.52 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | 7,385,180.00 | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Astrazeneca Pharma India Ltd | 12.96bn | 1.62bn | 179.32bn | 940.00 | 111.02 | 25.19 | 101.62 | 13.84 | 64.60 | 64.60 | 518.21 | 284.77 | 1.26 | 2.84 | 9.79 | 13,782,230.00 | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 54.64 | 12.47 | 10.27 | 1.97 | 141.26 | 0.0064 | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
Data as of Jul 26 2024. Currency figures normalised to Granules India Ltd's reporting currency: Indian Rupee INR
21.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Singapore) Ltd.as of 31 May 2024 | 13.81m | 5.70% |
| Axis Asset Management Co. Ltd.as of 30 Jun 2024 | 6.36m | 2.62% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2023 | 5.58m | 2.30% |
| quant Money Managers Ltd.as of 28 Jun 2024 | 5.34m | 2.20% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 5.25m | 2.17% |
| Schroder Investment Management Ltd.as of 31 Mar 2024 | 4.79m | 1.98% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 4.08m | 1.69% |
| Norges Bank Investment Managementas of 30 Sep 2023 | 2.79m | 1.15% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Jun 2024 | 2.64m | 1.09% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 2.63m | 1.09% |
More ▼
Data from 31 Dec 2023 - 15 Jul 2024Source: FactSet Research Systems Inc.
